BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor antigen vaccine for ovarian cancer, as well as and Covid-T, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and Covid-T; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its Covid-T immunodiagnostic. The company is headquartered in Vancouver, Canada.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.14    OTCQB
As of 01/27/2022     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Index country:  Canada
Country of incorporation:  
IPO date:  06/21/2021
Outstanding shares:  92,246,483
Average volume:  119,585
Market cap:   $13,080,551
Current dividend yield:  0.00%
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.38
PS ratio:   0.00
Return on equity:   -50.77%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy